This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00864006
First received: March 17, 2009
Last updated: March 27, 2017
Last verified: March 2009
  Purpose
The purpose of this study is to demonstrate the bioequivalence of divalproex sodium 125 MG delayed release tablets.

Condition Intervention Phase
Seizures Drug: Divalproex Sodium Drug: Depakote DR Tablets Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence according to US FDA Guidelines [ Time Frame: 9 Days ]

Enrollment: 28
Study Start Date: October 2006
Study Completion Date: October 2006
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
Drug: Divalproex Sodium
Active Comparator: 2
Depakote 125 MG DR Tablets Abbott Laboratories USA
Drug: Depakote DR Tablets

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant findings on physical examination, medical history or laboratory tests on screening

Exclusion Criteria:

  • Positive test for HIV or Hepatitis B and C
  • History of sensitivity to valproic acid or related compounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00864006

Sponsors and Collaborators
Sandoz
Investigators
Principal Investigator: Xueyu Chen, MD, Ph.D, FRCP(C) Pharma Medica Research, Inc.
  More Information

Responsible Party: Eric Mitleberg. Ph.D., VP Product Development, Sandoz, Inc.
ClinicalTrials.gov Identifier: NCT00864006     History of Changes
Other Study ID Numbers: 2006-1294
Study First Received: March 17, 2009
Last Updated: March 27, 2017

Additional relevant MeSH terms:
Seizures
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Valproic Acid
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on June 22, 2017